급성 흥분 및 공격성 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)
Global Acute Agitation And Aggression Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
상품코드:1578213
리서치사:Value Market Research
발행일:2024년 09월
페이지 정보:영문 231 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
급성 흥분 및 공격성 치료 시장의 세계 수요는 2023년 48억 5,000만 달러에서 2032년 거의 80억 2,000만 달러의 시장 규모에 도달할 것으로 추정되며, 2024-2032년 조사 기간 동안 5.75%의 CAGR을 기록할 것으로 예상됩니다.
급성 흥분은 비정상적인 운동 활동의 유무에 관계없이 내적 긴장과 불안의 상태를 말합니다. 반면, 급성 공격성은 자해나 타인에게 해를 끼칠 수 있는 행동적 표현을 의미합니다. 급성 흥분과 공격성 치료는 흥분과 공격성을 치료하기 위해 환자에게 행해지는 의료 행위일 뿐입니다. 일반적으로 우울증, 양극성 장애, 알코올 중독, 호르몬 균형 장애, 자폐증, 스트레스, 신경 장애 등의 원인으로 인해 급성 흥분과 공격성이 유발됩니다. 급성 흥분과 공격성을 치료하면 평온함을 되찾는 데 도움이 될 수 있습니다.
시장 역학
세계 급성 흥분 및 공격성 치료 시장은 정신질환의 조급증 및 공격성 진단 증가, 정신질환의 경제적 부담 증가, 인식 확산을 위한 조직 형성으로 인해 인기를 끌고 있습니다. 정신질환 환자의 조급증 및 공격성 진단에 대한 인식의 변화와 치료에 대한 인식이 높아짐에 따라 세계 급성 조급증 및 공격성 치료 시장의 성장을 촉진할 것으로 예상됩니다. 또한, 급성 조울증 및 공격성에 대한 새로운 치료법의 연구 개발이 시장 성장을 촉진할 것으로 예상됩니다. 정신 질환의 증가, 노인 인구의 치매 발병률 증가, 환자의 조급증, 항정신병 약물 처방 증가는 향후 몇 년 동안 급성 흥분 및 공격성 치료 시장의 성장을 촉진할 것으로 예상됩니다.
조사 보고서는 Porter's Five Forces 모델, 시장 매력도 분석, 밸류체인 분석을 다루고 있습니다. 이러한 도구는 산업 구조를 명확하게 파악하고 세계 수준에서 경쟁의 매력을 평가하는 데 도움이됩니다. 또한 이러한 도구는 급성 흥분 및 공격성 치료 세계 시장에서 각 부문을 포괄적으로 평가할 수 있습니다. 급성 흥분 및 공격성 치료 산업의 성장과 동향은 이 조사에 대한 전체적인 접근 방식을 제공합니다.
맞춤형 요구사항이 있는 경우, 저희에게 연락주시기 바랍니다. 당사의 조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.
The global demand for Acute Agitation And Aggression Treatment Market is presumed to reach the market size of nearly USD 8.02 Billion by 2032 from USD 4.85 Billion in 2023 with a CAGR of 5.75% under the study period 2024-2032.
Acute Agitation refers to the state of inner tension or unease with or without abnormal motor activity. While acute aggression signifies a behavioural expression with the potential to self-harm or harm others. Acute agitation and aggressive treatment are nothing but the medical care given to a patient to get cured of agitation and aggression. Generally, acute agitation and aggression are caused in an individual due to reasons like depression, bipolar disorder, alcohol dependency, hormonal imbalances, autism, stress, and neurological disorders. Acute agitation and aggression treatment can help in restoring the sense of calm.
MARKET DYNAMICS
The global acute agitation and aggression treatment market is gaining popularity owing to the rise in the agitation and aggression diagnosis in psychological illnesses, the increase in the economic burden of psychological illness, and the formation of an organization to spread awareness. Altering attitudes toward agitation and aggression diagnosis among mentally ill patients and an increase in awareness about treatments are likely to fuel the global acute agitation and aggression treatment market growth. Additionally, research and development of novel treatments for acute agitation and aggression are expected to drive market growth. The rise in mental illness, increase in dementia incidences among the geriatric population, the rush in agitation in patients, and an increase in prescriptions of anti-psychotics are boosting the growth of the acute agitation and aggression treatment market in the forthcoming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Agitation And Aggression Treatment. The growth and trends of Acute Agitation And Aggression Treatment industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Acute Agitation And Aggression Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Global Acute Agitation And Aggression Treatment Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Agitation And Aggression Treatment market include Eli Lilly And Company, Pfizer Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3. ACUTE AGITATION AND AGGRESSION TREATMENT - INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Treatment Approach
3.7.2 Market Attractiveness Analysis By Indication
3.7.3 Market Attractiveness Analysis By Route of Administration
3.7.4 Market Attractiveness Analysis By End User
3.7.5 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY TREATMENT APPROACH
5.1. Overview By Treatment Approach
5.2. Historical and Forecast Data Analysis By Treatment Approach
5.3. Behavioral Approaches Historic and Forecast Sales By Regions
5.4. Environmental Interventions Historic and Forecast Sales By Regions
5.5. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Historic and Forecast Sales By Regions
6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY INDICATION
6.1. Overview By Indication
6.2. Historical and Forecast Data Analysis By Indication
6.3. Schizophrenia Historic and Forecast Sales By Regions
6.4. Dementia Historic and Forecast Sales By Regions
6.5. Bipolar Disorder Historic and Forecast Sales By Regions
6.6. Depression Historic and Forecast Sales By Regions
6.7. Drug-induced Agitation and Aggression Historic and Forecast Sales By Regions
6.8. Alcohol Withdrawal Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions
7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1. Overview By Route of Administration
7.2. Historical and Forecast Data Analysis By Route of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Intramuscular Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions
8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY END USER
8.1. Overview By End User
8.2. Historical and Forecast Data Analysis By End User
8.3. Hospitals & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
8.4. Psychiatric Care Facilities Historic and Forecast Sales By Regions
8.5. Others Historic and Forecast Sales By Regions
9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE ACUTE AGITATION AND AGGRESSION TREATMENT COMPANIES
10.1. Acute Agitation And Aggression Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Eli Lilly And Company
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. Pfizer Inc.
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Otsuka Holdings
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. GlaxoSmithKline
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. H. Lundbeck A/S
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. Johnson & Johnson
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. Teva Pharmaceutical Industries Ltd.
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. Amneal Pharmaceuticals LLC
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. Sun Pharmaceutical Industries Ltd.
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. F. Hoffmann-La Roche Ltd
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
11.13. Bausch Health Companies Inc.
11.13.1 Company Overview
11.13.2 Company Revenue
11.13.3 Products
11.13.4 Recent Developments
11.14. Apotex Inc.
11.14.1 Company Overview
11.14.2 Company Revenue
11.14.3 Products
11.14.4 Recent Developments
11.15. Aurobindo Pharma
11.15.1 Company Overview
11.15.2 Company Revenue
11.15.3 Products
11.15.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
